- Home
- URGN vs CZWI Comparison
URGN vs CZWI Comparison
Compare URGN & CZWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CZWI
- Stock Information
- Founded
- URGN 2004
- CZWI 1938
- Country
- URGN United States
- CZWI United States
- Employees
- URGN N/A
- CZWI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CZWI Savings Institutions
- Sector
- URGN Health Care
- CZWI Finance
- Exchange
- URGN Nasdaq
- CZWI Nasdaq
- Market Cap
- URGN 181.2M
- CZWI 147.8M
- IPO Year
- URGN 2017
- CZWI N/A
- Fundamental
- Price
- URGN $14.82
- CZWI $13.33
- Analyst Decision
- URGN Strong Buy
- CZWI
- Analyst Count
- URGN 9
- CZWI 0
- Target Price
- URGN $26.81
- CZWI N/A
- AVG Volume (30 Days)
- URGN 5.9M
- CZWI 19.9K
- Earning Date
- URGN 08-12-2025
- CZWI 07-28-2025
- Dividend Yield
- URGN N/A
- CZWI 2.71%
- EPS Growth
- URGN N/A
- CZWI N/A
- EPS
- URGN N/A
- CZWI 1.27
- Revenue
- URGN $91,871,000.00
- CZWI $58,040,000.00
- Revenue This Year
- URGN $36.65
- CZWI N/A
- Revenue Next Year
- URGN $88.35
- CZWI $13.16
- P/E Ratio
- URGN N/A
- CZWI $10.45
- Revenue Growth
- URGN 8.98
- CZWI N/A
- 52 Week Low
- URGN $3.42
- CZWI $10.92
- 52 Week High
- URGN $18.15
- CZWI $17.04
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- CZWI 27.12
- Support Level
- URGN $6.92
- CZWI $13.30
- Resistance Level
- URGN $15.22
- CZWI $14.50
- Average True Range (ATR)
- URGN 1.57
- CZWI 0.37
- MACD
- URGN 1.17
- CZWI -0.13
- Stochastic Oscillator
- URGN 96.49
- CZWI 0.00
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CZWI Citizens Community Bancorp Inc.
Citizens Community Bancorp Inc is a bank holding company that offers traditional community banking services to businesses, Agricultural operators, and consumers, including one-to-four-family residential mortgages. it also offers a variety of loan products including commercial real estate loans, commercial and industrial (C&I) loans, agricultural real estate loans, agricultural operating loans, residential mortgages, home equity lines-of-credit, and consumer loans and offers deposit products through its branches, including demand deposits, various savings and money-market accounts and certificates of deposit. The company's sources of funds are deposits; amortization, prepayments, and maturities of outstanding loans; other short- term investments; and funds provided from operations.